Initiative

Initiative is a French biotechnology company dedicated to discovering and developing first-in-class small molecule therapeutics for "undruggable" targets in oncology. The company utilizes a proprietary fragment-based drug discovery (FBDD) platform combined with advanced biophysical techniques to identify novel binding sites on high-value proteins. Their primary focus is on transcription factors and other challenging targets, such as MYC, that have historically eluded traditional drug discovery efforts. By integrating structural biology and medicinal chemistry, Initiative aims to provide new treatment options for patients with aggressive cancers. The company is headquartered in Marseille and was founded by leading scientists from the French National Centre for Scientific Research (CNRS).